OncoMed Pharmaceuticals Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
OncoMed Pharma (OMED) Reports In-Line Q3 EPS
November 1, 2016 5:17 PM EDTOncoMed Pharma (NASDAQ: OMED) reported Q3 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $9.48 million.
Cash, cash equivalents and short-term investments totaled $207.6 million as of September 30, 2016, compared to $171.5 million as... More
